Efficacy and safety of edoxaban in the treatment of venous thromboembolism

Edoxaban is an oral, direct, selective FXa inhibitor, which is characterized by rapid absorption (1–3 h) and an elimination half-life of approximately 8 to 10 h in humans. The safety of edoxaban in patients with nonvalvular atrial fibrillation and its efficacy and safety for prevention of venous thromboembolism (VTE) in patients undergoing major orthopedic surgery, as well as treatment of VTE has been assessed in large clinical trials. null null...